Key result
Administration of SR121566A significantly increased vessel patency compared to saline control (80% vs 20%, P<0.01) in a rabbit model of microvascular thrombosis.
Why the study?
Does SR121566A prevent microvascular thrombosis and improve vessel patency in a rabbit ear artery injury model?
Population
20 rabbits (40 arteries) in a rabbit ear artery model with standardized arterial injury
Comparison
SR121566A 2 mg/kg bolus vs Saline injection, acetylsalicylic acid 10 mg/kg…
Design
Preclinical, coded, double-blind
Follow-up
120 minutes
Authors
Loading...
Supports further preclinical testing of SR121566A; leaves open translation to human microvascular procedures.
RCT (n=20)
Double-blind
Does SR121566A prevent microvascular thrombosis and improve vessel patency in a rabbit ear artery injury model?
Absolute Event Rate: 80% vs 20%
p-value: p=<0.01
The glycoprotein IIb/IIIa inhibitor SR121566A significantly improved vessel patency in a rabbit model of microvascular thrombosis without deleterious effects on bleeding times.
Ching et al. (2003) conducted an RCT in microsurgical thrombosis (n=20). SR121566A vs. saline injection was evaluated on vessel patency at 35 minutes after reperfusion (p=<0.01). Administration of SR121566A significantly increased vessel patency compared to saline control (80% vs 20%, P<0.01) in a rabbit model of microvascular thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: